CUMBERLAND PHARMACEUTICALS Business Summary

Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company that generates revenue primarily through the acquisition, development, and commercialization of branded prescription products. Its business model is centered on a single operating segment: specialty pharmaceutical products, which targets four primary medical markets: hospital acute care, gastroenterology, rheumatology, and oncology. The company’s commercial portfolio includes key FDA-approved brands such as Acetadote (acetaminophen poisoning), Caldolor (pain and fever), Kristalose (laxative), and the recently added Talicia (H. pylori infection). Cumberland utilizes a multi-channel distribution strategy involving hospital, field, and oncology sales divisions in the U.S., complemented by a network of international partners for global reach. Direct competitors include specialty peers such as ANI Pharmaceuticals, Collegium Pharmaceutical, Supernus Pharmaceuticals, and Ironwood Pharmaceuticals; within this landscape, Cumberland distinguishes itself as a niche player focused on high-margin, underserved therapeutic areas and the lifecycle management of established brands. The company was founded in 1999 by A.J. Kazimi, who serves as Chairman and CEO and brings over 30 years of biopharmaceutical experience, including a prior leadership role at Therapeutic Antibodies Inc. The executive team is led by John M. Hamm, Vice President and Chief Financial Officer, who possesses over 25 years of finance experience from organizations like HealthSpring (now Cigna), and James L. Herman, Executive Vice President of National Accounts and Chief Compliance Officer. The leadership is supported by a seasoned Board of Directors, including Dr. Gordon R. Bernard, a Melinda Owen Bass Professor at Vanderbilt University, and Kenneth J. Krogulski, Managing Partner at Berkshire Asset Management. Notable institutional investors include Renaissance Technologies, Millennium Management, and Dimensional Fund Advisors, reflecting a stable base of professional backing for the company’s long-term growth strategy in the specialty drug market.